These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2060537)

  • 1. Pharmacokinetic profile and tolerability of pimobendan in patients with terminal renal insufficiency.
    Przechera M; Roth W; Kühlkamp V; Risler T; Haehl M
    Eur J Clin Pharmacol; 1991; 40(1):107-11. PubMed ID: 2060537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Chu KM; Shieh SM; Hu OY
    Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.
    Chu KM; Shieh SM; Hu OY
    Eur J Clin Pharmacol; 1995; 47(6):537-42. PubMed ID: 7768258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamic modeling of pimobendan in healthy normal subjects.
    Chu KM; Hu OY; Shieh SM
    Drug Metab Dispos; 1999 Jun; 27(6):701-9. PubMed ID: 10348800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.
    Yata M; McLachlan AJ; Foster DJ; Hanzlicek AS; Beijerink NJ
    J Vet Cardiol; 2016 Dec; 18(4):310-325. PubMed ID: 27613648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects.
    Clifton GD; Harrison MR; Wermeling DP; Long RA; Fleck RJ; Rolleri RL; Weller S; Brown AR; Welch RM
    Clin Pharmacol Ther; 1994 Jan; 55(1):55-63. PubMed ID: 8299318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
    Antila S; Honkanen T; Lehtonen L; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravenous pimobendan (UDCG 115 BS) on hemodynamics and left ventricular volumes in idiopathic dilative cardiomyopathy.
    Permanetter B; Sebening H; Hartmann F; Baumann G; Lutilsky L
    J Cardiovasc Pharmacol; 1989 Dec; 14(6):803-9. PubMed ID: 2481765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
    Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
    Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemodynamic dose-efficacy of levosimendan in healthy volunteers.
    Lilleberg J; Sundberg S; Häyhä M; Akkila J; Nieminen MS
    Eur J Clin Pharmacol; 1994; 47(3):267-74. PubMed ID: 7867680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of pimobendan in healthy mature horses.
    Afonso T; Giguère S; Rapoport G; Barton MH; Coleman AE
    Equine Vet J; 2016 May; 48(3):352-6. PubMed ID: 25758404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cytochrome P-450 isoform(s) responsible for the metabolism of pimobendan in human liver microsomes.
    Kuriya Si; Ohmori S; Hino M; Ishii I; Nakamura H; Senda C; Igarashi T; Kiuchi M; Kitada M
    Drug Metab Dispos; 2000 Jan; 28(1):73-8. PubMed ID: 10611143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure.
    Ishiki R; Ishihara T; Izawa H; Nagata K; Hirai M; Yokota M
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):897-905. PubMed ID: 10836724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of pimobendan enantiomers after oral and intravenous administration of racemate pimobendan formulations in healthy dogs.
    Bell ET; Devi JL; Chiu S; Zahra P; Whittem T
    J Vet Pharmacol Ther; 2016 Feb; 39(1):54-61. PubMed ID: 25989021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.
    Marichal JF; Brunel P; Lecaillon JB; Godbillon J; Faller B; Brignon P; Ménard J
    Eur J Drug Metab Pharmacokinet; 1992; 17(3):213-20. PubMed ID: 1490491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of oral pimobendan in healthy cats.
    Hanzlicek AS; Gehring R; Kukanich B; Kukanich KS; Borgarelli M; Smee N; Olson EE; Margiocco M
    J Vet Cardiol; 2012 Dec; 14(4):489-96. PubMed ID: 23116650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.